Literature DB >> 20167810

Akt2 and Akt3 play a pivotal role in malignant gliomas.

Hideo Mure1, Kazuhito Matsuzaki, Keiko T Kitazato, Yoshifumi Mizobuchi, Kazuyuki Kuwayama, Teruyoshi Kageji, Shinji Nagahiro.   

Abstract

Akt, one of the major downstream effectors of phosphatidylinositol 3-kinase, is hyper-expressed and activated in a variety of cancers including glioblastoma. However, the expression profiles of the Akt isoforms Akt1/PKBalpha, Akt2/PKBbeta, and Akt3/PKBgamma and their functional roles in malignant glioma are not well understood. Therefore, we examined the protein and mRNA expression patterns of Akt isoforms in tissues from human astrocytomas, glioblastomas, and non-neoplastic regions. We also explored the biological role of each Akt isoform in malignant glioma cells using RNA interference-mediated knock-down and the over-expression of plasmid DNA of each isoform. The expression of Akt1 protein and mRNA was similar in glioma and normal control tissues. Although the protein and mRNA level of Akt2 increased with the pathological grade of malignancy, the expression of Akt3 mRNA and protein decreased as the malignancy grade increased. In U87MG, T98G, and TGB cells, the down-regulation of Akt2 or Akt3 by RNA interference reduced the expression of the phosphorylated form of Bad, resulting in the induction of caspase-dependent apoptosis. Akt1 knock-down did not affect cell growth or survival. We first demonstrate that the over-expression of Akt2 or Akt3 down-regulated the expression of the other protein and that endogenous Akt3 protein showed high kinase activity in U87MG cells. Our data suggest that Akt2 and Akt3 play an important role in the viability of human malignant glioma cells. Targeting Akt2 and Akt3 may hold promise for the treatment of patients with gliomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20167810      PMCID: PMC2940586          DOI: 10.1093/neuonc/nop026

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  42 in total

Review 1.  Cellular survival: a play in three Akts.

Authors:  S R Datta; A Brunet; M E Greenberg
Journal:  Genes Dev       Date:  1999-11-15       Impact factor: 11.361

2.  Glioblastoma multiforme: the terminator.

Authors:  E C Holland
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 3.  Malignant glioma: genetics and biology of a grave matter.

Authors:  E A Maher; F B Furnari; R M Bachoo; D H Rowitch; D N Louis; W K Cavenee; R A DePinho
Journal:  Genes Dev       Date:  2001-06-01       Impact factor: 11.361

4.  In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).

Authors:  L Hu; C Zaloudek; G B Mills; J Gray; R B Jaffe
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

5.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.

Authors:  E C Holland; J Celestino; C Dai; L Schaefer; R E Sawaya; G N Fuller
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

6.  Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.

Authors:  Y Sonoda; T Ozawa; K D Aldape; D F Deen; M S Berger; R O Pieper
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

7.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.

Authors:  M Sun; G Wang; J E Paciga; R I Feldman; Z Q Yuan; X L Ma; S A Shelley; R Jove; P N Tsichlis; S V Nicosia; J Q Cheng
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

8.  Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta).

Authors:  H Cho; J Mu; J K Kim; J L Thorvaldsen; Q Chu; E B Crenshaw; K H Kaestner; M S Bartolomei; G I Shulman; M J Birnbaum
Journal:  Science       Date:  2001-06-01       Impact factor: 47.728

9.  Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NFkappaB activation in glioblastoma.

Authors:  Kazuyuki Kuwayama; Kazuhito Matsuzaki; Yoshihumi Mizobuchi; Hideo Mure; Keiko T Kitazato; Teruyoshi Kageji; Mitsuyoshi Nakao; Shinji Nagahiro
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

Review 10.  The developmental biology of brain tumors.

Authors:  R Wechsler-Reya; M P Scott
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

View more
  47 in total

1.  High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression.

Authors:  Junxia Zhang; Kai Huang; Zhendong Shi; Jian Zou; Yingyi Wang; Zhifan Jia; Anling Zhang; Lei Han; Xiao Yue; Ning Liu; Tao Jiang; Yongping You; Peiyu Pu; Chunsheng Kang
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  OverAKT3: tumor progression and chemoresistance.

Authors:  Ping Ji; Kristen M Turner; Wei Zhang
Journal:  Cell Cycle       Date:  2015-04-30       Impact factor: 4.534

3.  Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.

Authors:  Paul A Clark; Saswati Bhattacharya; Ardem Elmayan; Soesiawati R Darjatmoko; Bradley A Thuro; Michael B Yan; Paul R van Ginkel; Arthur S Polans; John S Kuo
Journal:  J Neurosurg       Date:  2016-07-15       Impact factor: 5.115

4.  Growth inhibition of malignant glioblastoma by DING protein.

Authors:  Markus J Bookland; Nune Darbinian; Michael Weaver; Shohreh Amini; Kamel Khalili
Journal:  J Neurooncol       Date:  2011-11-04       Impact factor: 4.130

5.  Cytotoxic Effects of Environmental Toxins on Human Glial Cells.

Authors:  Fiona D'Mello; Nady Braidy; Helder Marçal; Gilles Guillemin; Fanny Rossi; Mirielle Chinian; Dominique Laurent; Charles Teo; Brett A Neilan
Journal:  Neurotox Res       Date:  2016-10-29       Impact factor: 3.911

6.  Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.

Authors:  Mahesh Seetharam; Alice C Fan; Mai Tran; Liwen Xu; John P Renschler; Dean W Felsher; Kunju Sridhar; Francois Wilhelm; Peter L Greenberg
Journal:  Leuk Res       Date:  2011-09-14       Impact factor: 3.156

7.  MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.

Authors:  Haiqian Liang; Renjie Wang; Ying Jin; Jianwei Li; Sai Zhang
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

8.  Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.

Authors:  Kristen M Turner; Youting Sun; Ping Ji; Kirsi J Granberg; Brady Bernard; Limei Hu; David E Cogdell; Xinhui Zhou; Olli Yli-Harja; Matti Nykter; Ilya Shmulevich; W K Alfred Yung; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-03       Impact factor: 11.205

Review 9.  Akt inhibitors in clinical development for the treatment of cancer.

Authors:  Sumanta Kumar Pal; Karen Reckamp; Hua Yu; Robert A Figlin
Journal:  Expert Opin Investig Drugs       Date:  2010-09-16       Impact factor: 6.206

10.  In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog.

Authors:  Charng Choon Wong; Nagarajan Periasamy; Sreenivasa Rao Sagineedu; Shiran Sidik; Shariful Hasan Sumon; Paul Loadman; Roger Phillips; Nordin Haji Lajis; Johnson Stanslas
Journal:  Invest New Drugs       Date:  2014-05-31       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.